BMO Hosts Third Annual Metabolic Health Summit on the Future of the GLP-1+ Market

BMO (NYSE:BMO) will host the 2026 Metabolic Health Summit in New York on March 24, 2026, convening BioPharma innovators, clinical experts, and investors to discuss GLP-1–based therapies and metabolic disease trends.

Rhea-AI Summary

BMO (NYSE:BMO) will host the 2026 Metabolic Health Summit in New York on March 24, 2026, convening BioPharma innovators, clinical experts, and investors to discuss GLP-1–based therapies and metabolic disease trends.

The in-person event runs 7:30 a.m.–4:30 p.m. ET at the Westin Grand Central and features panels, fireside chats, and analyst-led discussions.

Argus Mar 10 session

+0.77% close to close Open Argus

Details

News Market Reaction – BMO

On Mar 10, the day this news came out, BMO closed 0.77% above the previous close.

Data tracked by StockTitan Argus for the Mar 10 session.

Market Context

This announcement highlights BMO Capital Markets’ expansion into metabolic and cardiometabolic theme...

Analysis

This announcement highlights BMO Capital Markets’ expansion into metabolic and cardiometabolic themes, leveraging the growing GLP-1+ market through its Metabolic Health Summit on March 24, 2026. It follows other thought-leadership events and sector reports, reinforcing BMO’s research-driven brand. Investors may watch how this franchise deepens relationships with BioPharma clients and whether it complements core drivers such as earnings growth and dividend stability.

Key Figures

Summit date: March 24, 2026 Summit hours: 7:30 a.m. – 4:30 p.m. ET Event floor: 3rd Floor +2 more

Summit date

March 24, 2026

Date of BMO Metabolic Health Summit 2026 in New York

Summit hours

7:30 a.m. – 4:30 p.m. ET

Event duration for the Metabolic Health Summit

Event floor

3rd Floor

Westin Grand Central event location floor

Street address

212 E 42nd St

Venue address for the Metabolic Health Summit

Third annual summit

Third annual

Indicates ongoing series of Metabolic Health/Obesity summits

Historical Context

5 past events · Latest: Mar 04

5 events

1. Mar 04

   Industry report teaser

   24h Move

   +1.6%

   Announcement of third annual Wine Market Report and expanded partnerships.

2. Feb 25

   Dividend declaration

   24h Move

   +4.1%

   Quarterly common dividend of $1.67 per share and preferred dividends declared.

3. Feb 25

   Earnings release

   24h Move

   +4.1%

   Q1 2026 net income and EPS growth plus acquisition and buyback details.

4. Feb 11

   Investor conference

   24h Move

   -1.4%

   Hosting Global Metals, Mining & Critical Minerals Conference with industry leaders.

5. Feb 05

   Recognition/award

   24h Move

   -0.7%

   Executive named to Top 100 AI Leaders list highlighting AI initiatives.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

glp-1, glp-1+ therapy, cardiometabolic

3 terms

glp-1 medical

"impact of GLP-1–based therapies across obesity, diabetes, heart failure, and renal health"

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

glp-1+ therapy medical

"Insights from patients on GLP-1+ therapy"

GLP‑1+ therapy refers to a medical treatment that uses a GLP‑1 (glucagon‑like peptide‑1) drug—often combined with one or more additional medicines or modalities—to control blood sugar and reduce body weight. Think of it as a lead medication paired with companion treatments to boost effectiveness or reduce side effects; for investors, these combinations matter because they can expand patient use, change pricing and reimbursement, and affect a drug’s commercial value and regulatory pathway.

cardiometabolic medical

"advancement of metabolic, cardiovascular, and cardiometabolic science—including the broad and growing impact"

Cardiometabolic describes health conditions that affect the heart and the body’s metabolism—most commonly heart disease, high blood pressure, type 2 diabetes and obesity—that often occur together and share common causes. Investors care because these linked conditions drive large, predictable demand for drugs, medical devices and long-term care, and changes in treatment options, guidelines or costs can materially affect healthcare company revenues and government spending much like a problem in an engine and its fuel system impacts the whole vehicle.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Healthcare industry experts and leaders to convene March 24 at the 2026 BMO Metabolic Health Summit (formerly the Obesity Summit) to examine outlook and trends in metabolic disease and drug therapies

NEW YORK, March 10, 2026 /PRNewswire/ - BMO Capital Markets will host its 2026 Metabolic Health Summit, the next evolution of its former Obesity Summit in New York on March 24^th, 2026. This summit reflects the rapid advancement of metabolic, cardiovascular, and cardiometabolic science—including the broad and growing impact of GLP-1–based therapies across obesity, diabetes, heart failure, and renal health. The summit will convene industry-leading BioPharma innovators, experts, and investors for a full day of thought leadership panels, fireside conversations with corporate management, and small-group or one-on-one meetings exploring the future of metabolic health innovation.

What:	BMO Metabolic Health Summit 2026
	Hosted & moderated by Evan Seigerman,
	Head of Healthcare Research, BMO Capital Markets
Who:	Industry leading BioPharma innovators, experts and investors
When:	Tuesday, March 24, 2026 • 7:30 a.m. – 4:30 p.m. ET
Where:	Westin Grand Central – 3rd Floor
	212 E 42nd St, New York, NY 10017
	In-person only (no webcast)

The BMO Metabolic Health Summit will deliver thought leadership and corporate management perspectives in a variety of formats such as fireside chats, expert panels and presentations, including:

• Discussions hosted by BMO analysts with leading life sciences companies, including Aardvark Therapeutics, Amgen, Ascletis Pharma, Biomea Fusion, Corbus Pharmaceuticals, Eli Lilly & Co., Novo Nordisk, Pfizer, and Structure Therapeutics
• Obesity 103 with Katherine Saunders, MD, Obesity Physician & Co-Founder, FlyteHealth
• A discussion on the state of Obesity Medicine in 2026 with Dr. Louis J. Aronne, M.D., Sanford I. Weill Professor of Metabolic Research, Weill Cornell Medical College
• Panels on care delivery, emerging technologies, coverage and access ft. WeightWatchers, Metaphore Biotechnologies, Nuevocor Therapeutics, ProCare Rx, Ro Health, Superluminal Medicines, and Virta Health
• Insights from patients on GLP-1+ therapy

For more information or to request an interview with one of BMO's equity research analysts, please contact BMO Media Relations using the contact details below. Note: There may be restrictions for media on access to some presentations.

Event Resources: Agenda, Participating Companies

About BMO Financial Group 

BMO Financial Group is the eighth largest bank in North America by assets, with total assets of $1.5 trillion as of January 31, 2026. Serving clients for 200 years and counting, BMO is a diverse team of highly engaged employees providing a broad range of personal and commercial banking, wealth management, global markets and investment banking products and services to approximately 13 million clients across Canada, the United States, and in select markets globally. Driven by a single purpose, to Boldly Grow the Good in business and life, BMO is committed to driving positive change in the world, and making progress for a thriving economy, sustainable future, and stronger communities.   

View original content:https://www.prnewswire.com/news-releases/bmo-hosts-third-annual-metabolic-health-summit-on-the-future-of-the-glp-1-market-302708732.html

SOURCE BMO Financial Group

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When and where is the BMO Metabolic Health Summit (BMO) on March 24, 2026?

The summit takes place March 24, 2026, 7:30 a.m.–4:30 p.m. ET at the Westin Grand Central in New York. According to the company, the event is in-person only and will not be webcast, so onsite attendance is required.

Who is hosting and moderating the March 24, 2026 BMO Metabolic Health Summit (BMO)?

Evan Seigerman, Head of Healthcare Research at BMO, is hosting and moderating the summit. According to the company, BMO analysts will lead discussions with industry management, experts, and investors throughout the day.

Which companies and speakers are participating in the BMO Metabolic Health Summit (BMO) on March 24, 2026?

Participants include life sciences companies such as Eli Lilly, Novo Nordisk, Pfizer, Amgen, and others plus clinical leaders like Dr. Louis Aronne. According to the company, panels feature industry, payor, and patient perspectives on GLP-1+ therapies.

Will the BMO Metabolic Health Summit (BMO) on March 24, 2026 be available via webcast or remote attendance?

No, the event is in-person only with no webcast available. According to the company, media and investors should plan to attend on site; some presentations may have access restrictions for media.

How can investors or media request interviews or more information about the BMO Metabolic Health Summit (BMO)?

Contact BMO Media Relations to request interviews or access to analysts and presenters. According to the company, event resources include an agenda and list of participating companies for scheduling inquiries.